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Background.Although the optimal outcome of assisted reproductive technology (ART) is a healthy singleton pregnancy, the rate of
twin gestation from ART in women over the age of 35 is persistently high.Methods/Findings. We compared clinical pregnancy rates
(PRs), ongoing pregnancy/live birth rates, and multiple gestation rates (MGRs) in 108 women who chose elective single blastocyst
transfer (eSBT) to 415 women who chose elective double blastocyst transfer (eDBT) at a hospital-based IVF center. There was no
signiﬁcant diﬀerence in PR between eSBT and eDBT (57.4% versus 50.2%, P = 0.47) nor between eSBT and eDBT within each
age group: <35, 35–37, 38–40, and >40. The risk of multiple gestations, however, was greatly increased between eSBT and eDBT
(1.6 versus 32.4%, P<0.00005), and this diﬀerence did not vary across age groups. Conclusion(s). Women undergoing eDBT are
at uniformly high risk of multiple gestation regardless of age. eSBT appears to signiﬁcantly lower the risk of multiple gestation
without compromising PR.
1.Introduction
The optimal outcome of assisted reproductive technology
(ART) is a healthy singleton pregnancy [1]. The rate of twin
gestation from ART in women over the age of 35, however,
remains stable at 30%, and multiple gestations comprise a
quarter of all live births from fresh, nondonor cycles among
women aged 38–40 [2].
In 1998, the Society for Assisted Reproductive Tech-
nology (SART) and the American Society of Reproductive
Medicine (ASRM) issued the ﬁrst in a series of guidelines
regarding the optimal number of embryos to be transferred
based on patient age [3]. Aimed at reducing rates of high-
order multiple (HOM) pregnancies, these guidelines were
revised most recently in 2006 and recommend transferring
two to three cleavage stage embryos for women aged 35–37,
and no more than two blastocysts, depending on prognostic
factors and patient preference. For women aged 38–40 years,
the recommendation is for three to four cleavage stage
embryos, and between two to three blastocysts [4]. The
implementation of these guidelines has been associated with
a decrease in HOM [5], but the rate of twins remains persis-
tently high.
An extensive body of literature has demonstrated that
twin gestations carry increased risk of adverse outcomes,
such as prematurity, low birth weight, infant mortality [6, 7],
and maternal mortality [8]. Twin gestations also compound
the health threats to women of advanced maternal age, who
are already at increased risk of developing complications
such as gestational diabetes [9] and preeclampsia [10]. For
example, women over the age of 35 with preeclampsia have
three times the risk of pregnancy-related mortality than their
youngercounterparts[11].Theseadverseoutcomeshavehad
a considerable impact on public health and many have called
for policy change to decrease the prevalence of multiple
gestation.
Given that the transfer of multiple embryos increases the
risk of a multiple gestation, many have suggested a move2 ISRN Obstetrics and Gynecology
towards elective single embryo transfer(eSET), although this
recommendation has been focused mainly on women less
than age 36 [12]. Several randomized controlled trials in
Europe have demonstrated that eSET signiﬁcantly dimin-
ishes twin gestations and yields comparable live birth rates
in good prognosis patients [12, 13].
A handful of European studies have also addressed the
role of eSET in the advanced maternal age population. One
study found that eSET could be safely applied to patients
aged 36–39, while dramatically decreasing the multiple
gestation rate (MGR) and achieving similar pregnancy rates
(PRs) [14]. Another study found that eSET could be oﬀered
to women younger than 38 in the ﬁrst three IVF treatment
cycles without compromising PR, although the mean patient
age in this study was 32.5 years [15].
While these studies analyzing eSET have focused primar-
ily on day 3 embryo transfer, blastocyst transfer (BT) has
also emerged as a potential approach to reducing MGR as
generally fewer embryos are transferred. Several studies have
shown superior outcomes with BT compared to cleavage
stage embryo transfer [16–21]. The superior implantation
rate seen with BT has mainly been attributed to better
embryo selection.
A recent randomized prospective controlled trial found
higher PR with elective BT over the elective transfer of a
cleavage stage embryo [22]. This study, however, focused
only on women 36 years of age or less. Due to the paucity
of data regarding eSBT in the advanced maternal age pop-
ulation, we previously reviewed our preliminary experience
with eSBT in women older than 35 and found that PR was
quite promising, with half of the patients experiencing an
ongoing pregnancy or live birth [23]. More limited literature
existscomparingtheelectivesingleblastocysttransfer(eSBT)
with elective double blastocyst transfer (eDBT) between the
ages of 35 to 40. Although the inclusion criteria in these
studiesallowedpatientsuptoage37[24],38[25]or39,[26],
the focus tended to be on younger women.
As described previously, women of advanced maternal
age are at higher risk of maternal and perinatal adverse out-
comeswithtwingestation.Itiswiththesepatientsthatphysi-
c i a n st e n dt ob em o r ea g g r e s s i v ew i t hn u m b e ro fe m b r y o s
transferred as age has been demonstrated to be a powerful
negative predictor of IVF success [2]. Our hypothesis was
thatamongpatientswithblastocystsavailableforcryopreser-
vation, irrespective of advanced maternal age, eSBT would
yieldcomparablepregnancyratestoeDBT,whileminimizing
the risks of a multiple gestation. Therefore, our aim was
to compare pregnancy outcomes between eSBT and eDBT,
stratiﬁed by age. We were able to achieve this aim by utilizing
the methods described below.
2. Materials/Methods
All fresh nondonor cycles in which patients electively chose
to transfer one or two blastocysts at the Stanford Univer-
sity IVF program over a ﬁve-year period were analyzed.
The following ovarian stimulation protocols were used:
luteal down regulation (long), antagonist protocol, and
microdose leuprolide acetate (ﬂare), as previously described
[27]. Human chorionic gonadotropin (hCG) was generally
administered when at least two follicles reached an average
diameterof>17mm.Transvaginalultrasound-guidedoocyte
retrieval was performed 35 hours after hCG administration.
BT was oﬀered to patients with 3 or more 8-cell embryos on
day 3.
Prior to the start of their cycle, patients attended a group
IVF informational seminar, in which the advantages and
disadvantages of single versus multiple embryo transfer for
diﬀerent age groups were covered in detail. A preliminary
decision on the number of embryos to transfer was made at
the time of the patient’s initial IVF physician consultation,
where existing data from the literature and from our
own program regarding success rates and the incidence of
multiple gestation were further discussed, with emphasis on
the fetal and maternal risks of twin pregnancies. The ﬁnal
decision regarding how many blastocysts to transfer was
ultimately made by the patient at the time of transfer.
Sequential culture with P1/Blastocyst Medium (Irvine
Scientiﬁc, Santa Ana, Calif) or Quinn’s Advantage Cleav-
age/Blastocyst Media (SAGE In-Vitro-Fertilization, Inc.,
Trumbull, Conn) was used. The decision of which blastocyst
to transfer was based on the deﬁnition of the inner cell
mass and trophectoderm and the degree of expansion, with
the remaining blastocysts cryopreserved on day 5 or 6 as
previously described [28].
Ultrasound-guided embryo transfer was performed
using a Tefcat or Echotip Softpass catheter (Cook Ob/Gyn,
Spencer, Ind). Serum quantitative ß-hCG levels were
obtained at 8–10 days after embryo transfer. A clinical preg-
nancy was deﬁned as the presence of a fetal sac by transvagi-
nal ultrasound. An ongoing pregnancy was deﬁned as an
intrauterine pregnancy continuing past 14 weeks gestation.
Data collected in this study include age, number of
oocytes retrieved, number of embryos, number of blasto-
cysts cryopreserved, use of intracytoplasmic sperm injection
(ICSI)andpreimplantationgeneticdiagnosis(PGD),clinical
PR, live birth/ongoing PR, MGR, cesarean section rate, and
birthweight.Patientcharacteristicsandcycleoutcomesofthe
eSBT and eDBT groups were compared using t-test or Chi-
square test for normally distributed variables and Wilcoxon
rank-sum test for nonnormally distributed variables. Vari-
ables were tested for normality by the Kolmogorov-Smirnov
test and those that were not normally distributed were log-
arithmically transformed. Statistical signiﬁcance was deter-
mined as P<0.05. Age was analyzed as both a continuous
and a categorical variable (<35 years, 35–37 years, 38–40
years, and >40 years). We used one-way ANOVA to test
diﬀerences between age groups and adjusted for multiple
comparisons with the Scheﬀ´ e multiple-comparison test. A
generalized linear model was used to adjust for the potential
confounder of age and number of embryos transferred.
Statistical analyses were performed using Stata 9 (StataCorp
LP, College Station, Tex).
The study was approved by the Stanford University
Research Compliance Oﬃce for Human Subjects Research
(Institutional Review Board). Written consent was not
obtained from patients because this was a retrospective chartISRN Obstetrics and Gynecology 3
Table 1: Patient characteristics and cycle outcomes.
eSBT (n = 108) eDBT (n = 415) P value
Age, mean [SD] 33.9 [3.2] 35.0 [3.6] 0.0006a
Prior live birth (%) 28/108 (25.9) 76/339 (18.3) 0.08
Oocytes, mean [SD] 17.0 [6.3] 17.2 [6.5] 0.58
Embryos, mean [SD] 12.4 [5.8] 12.2 [4.9] 0.84
Blastocysts, meand [SD] 6.5 [3.8] 6.2 [3.0] 0.77
ICSI (%) 50/108 (46.3) 194/415 (46.7) 0.80
PGD (%) 9/108 (8.3) 25/415 (6.0) 0.28
Clinical PR (%) 62/108 (57.4) 207/415 (49.9) 0.16
Live birth/ongoing PR (%) 52/108 (48.1) 173/415 (41.7) 0.22
MGR (%) 1/62 (1.6) 67/207 (32.4) 0.00b
Cesarean rate (%) 12/38 (31.6) 61/161 (37.9) 0.47




dBlastocysts: mean includes blastocysts cryopreserved and transferred.
review, with the study design conceived after the patients’
treatments had been completed. Per the Stanford Insti-
tutional Review Board (IRB), an investigator can submit
a proposal for studying the treatment outcomes of past
patients whose treatments have been completed. It is not
routine to obtain prior consent of all patients utilizing
assisted reproductive technology for the possibility of using
their outcome data in a future study. Given that this study
was a retrospective chart review, the Stanford IRB granted
a waiver of consent. Every reproductive endocrinology and
infertility clinic in the United States must maintain outcome
data on assisted reproductive technology treatments because
this data must be reported to a nationally maintained
database.Alldataforourstudywascarefullydeidentiﬁedand
personal health information removed prior to analysis.
3. Results
Pregnancy outcomes in 108 women who chose eSBT were
compared to 415 women who chose eDBT. The mean age
of patients undergoing eDBT (35.0 years) was signiﬁcantly
higher than the mean age of patients undergoing eSBT (33.9
years) (P<0.006) (see Table 1). There were no diﬀerences
between the eSBT and eDBT groups in terms of prior live
births or cycle characteristics, such as number of oocytes,
number of embryos, number of blastocysts, and percent of
cycles using ICSI or PGD.
There was no signiﬁcant diﬀerence in live birth/ongoing
PR between the eSBT (48.1%) and eDBT (41.7%) groups
(P = 0.22) overall. The live birth/ongoing PR was similar for
eSBT and eDBT within each age group as well. Additionally,
we found no signiﬁcant diﬀerences in live birth/ongoing
PR or MGR when comparing the diﬀerent age groups
(<35 years, 35–37 years, 38–40 years, and >40 years) (see
Table 2).Logisticregressionrevealednosigniﬁcantdiﬀerence
in live birth/ongoing PR, controlling for number of embryos
transferred (OR 1.25, 95% CI 0.81–1.91) or for age (OR 0.96
per year, 95% CI 0.91–1.01).
The MGR was 32.4% for women who underwent eDBT,
compared with 1.6% in women who underwent eSBT (P<
0.00005). The one patient in the eSBT group with a multiple
gestation was less than 35 years of age and had monozygotic
twins. Among the eSBT and eDBT groups, there were two
cases of viable monozygotic twinning out of a total of 269
clinical pregnancies (0.7%). All multiple gestation births
were twins; there were no higher-order multiple births.
There were, however, two patients in the eDBT group
who initially had three viable fetuses on ﬁrst trimester
ultrasound. One patient initially had three separate gesta-
tional sacs of diﬀerent sizes, each containing a viable fetus,
and reported having intercourse four days prior to her
eDBT. The other patient had two gestational sacs, with one
viable singleton as well as viable monozygotic twins. Both
thesepatientsunderwentmultifetalpregnancyreductionand
delivered twins and a singleton, respectively.
There was no signiﬁcant diﬀerence in mode of delivery
between the eSBTs and eDBT groups. Mean birthweight
was signiﬁcantly smaller in the eDBT group (2832.2g)
compared with the eSBT group (3226.2g) (P = 0.001). The
mean birthweight of twin gestations (2369.7g) was lower
than the mean birthweight of singletons (3132.0g) (P<
0.0001). There was no signiﬁcant diﬀerence in the mean
birthweights of singletons resulting from eDBT (3078.7g)
and from eSBT (3285.7g) (P = 0.11). The 18.8% (19/101)
of singletons that were known to begin as a vanishing
twin gestation, however, had a signiﬁcantly lower mean
birthweight (2794.4g) compared to singletons that began as
such (3188.2g) (P = 0.04).
4. Discussion
In many European countries eSET is mandated by the
government and has become a part of routine clinical
practice [29]. In the United States, with most patients
facing considerable out-of-pocket costs per IVF cycle, many
patients and physicians are hesitant to move towards the4 ISRN Obstetrics and Gynecology
Table 2: Cycle characteristics and outcomes by age category.

















Oocytes, mean 16.7 17.4 17.5 17.9 16.3 15.7 23.0 17.5
Embryos, mean 12.6 12.3 12.5 12.5 11.1 11.4 13.0 13.3
Blastocysts, meane 6.6 6.6 6.7 6.3 5.6 5.4 4.0 5.9
Cryopreserved
blastocysts, mean 5.6 4.6 5.7 4.3 4.6 3.4 3.0 3.9
ICSI (%) 36/63 (57.1) 119/208 (57.2) 13/34 (38.2) 39/113 (34.5) 0/10 (0)a 29/81 (35.8)a 1/1 (100) 6/13 (46.1)
PGD (%) 4/63 (6.3) 13/208 (6.3) 4/34 (11.8) 6/113 (5.3) 1/10 (10.0) 4/81 (4.9) 0/1 (0) 2/13 (15.4)
Clinical PR (%) 37/63 (58.7) 113/208 (54.3) 19/34 (55.9) 52/113 (46.0) 5/10 (50.0) 35/81 (43.2) 1/1 (100) 7/13 (53.8)
Live birth/ongoing
PR (%) 32/63 (50.8) 97/208 (46.6) 16/34 (47.1) 43/113 (38.1) 3/10 (30.0) 28/81 (34.6) 1/1 (100) 5/13 (38.5)
MGR (%) 1/37 (2.7)b 36/113 (31.9)b 0/19 (0)c 17/52 (32.7)c 0/3 (0) 12/35 (34.3) 0/1 (0) 2/7 (28.6)
Cesarean rate (%) 6/22 (27.3) 38/90(42.2) 5/13(38.5) 9/39 (23.1) 0/3 (0) 11/27 (40.7) 1/1 (100) 3/5 (60.0)
Birthweight, mean





eBlastocysts: mean includes blastocysts cryopreserved and transferred.
transfer of a single embryo, for fear of compromising PR.
Our results show, however, that when additional blastocysts
are available for cryopreservation, eSBT can achieve com-
parable PR to eDBT across diﬀering age groups, up to age
38. In our study, eSBT also appeared to be a promising
option for women over the age of 38, although the analysis
of PR in this age group is limited, as there were fewer
eSBTs in this cohort, with only one patient in the >40 year
old group who transferred a single blastocyst. Importantly,
however, the MGR was approximately 30% in all age groups
undergoing eDBT, suggesting that advanced maternal age
does not protect against multiple gestations in this good
prognosis group.
Given the relatively small number of women over the
age of 38 in our study, it is diﬃcult to advocate a routine
policy ofsingle blastocysttransferinthis agegroup. Ourdata
are encouraging, however, regarding the option of eSBT for
older patients with blastocystsavailableforcryopreservation,
who prefer to avoid a multiple gestation. These results are in
accordance with the recent ﬁndings of Mullin et al., who also
suggested that women under the age of 40 can choose eSBT
as opposed to eDBT without reducing PR [26].
Despite the more limited numbers in our older cohort,
this study has the largest eSBT cohort used to compare
eSBT with eDBT in the United States and may provide
reassurance to physicians who are reluctant to oﬀer eSBT
to women of advanced maternal age. Clearly, eSBT must be
applied selectively to a good prognosis cohort. Randomized
prospective trials have demonstrated that, in an unselected
patient population, eSET can signiﬁcantly compromise PR
[30]. Our results suggest, however, that age alone should not
automatically prevent inclusion in a good prognosis cohort.
Among women with blastocysts available for cryopreser-
vation, age does not appear to confer a signiﬁcantly worse
prognosis, as PR was comparable up to age 38. Although a
larger proportion of younger women will have good quality
blastocysts, those older women with blastocysts available for
cryopreservation should not be excluded from the option of
eSBT, particularly as they are at substantial risk of MGR with
eDBT.
Among MGRs resulting from ART, studies have demon-
strated an increased risk of MZ twinning, with some
suggesting added risk for MZ twinning with BT [31]. We
have previously reported that with increased experience in
blastocyst culture and transfer, our overall blastocyst MZ
twinning rate decreased to within range of that seen with
cleavage stage transfer [32]. In this current study, our rate of
MZ twinning is double the rate reported for MZ twinning
in nature (0.4%) [33] but is in accordance with the MZ
twinning rates described in other retrospective series [34].
Interestingly, despite the higher proportion of twin
gestations in the eDBT group, there were similar rates
of cesarean delivery between the two groups. The high
percentage of multiple gestations among the patients who
underwent eDBT contributed to the lower birth weight seen
in this group, as twin gestations are known to be at higher
risk of preterm delivery and low birth weight. Another
contributing factor to the birth weight discordance appears
to be the presence of vanishing twins in the eDBT cohort.
Among the singletons born in the eDBT group, the survivors
of a vanishing twin gestation had a signiﬁcantly lower mean
birth weight, in keeping with previous studies [35, 36]. Thus,
even if eDBT ultimately yields a singleton gestation, there
may be adverse implications for the pregnancy through theISRN Obstetrics and Gynecology 5
implantation of more than one embryo. Physicians may wish
to consider this as well in deciding between eSBT and eDBT.
Duetotheretrospectivenatureofthestudy,uncontrolled
factorsmay have made the eDBTgroup less likely to conceive
than the eSBT group, resulting in patient and physician
decision to transfer an additional embryo. It is important to
note, however, that there were no diﬀerences in percentage of
patients with a prior live birth or mean number of oocytes,
embryos, or blastocysts between the eSBT and eDBT groups,
suggesting that overall these two cohorts comprised similar
populations.
The main strength of our study is that it presents the
largest eSBT cohort in the United States, in order to compare
eSBT with eDBT. Moreover, it is the most inclusive study
on this topic, as most other authors have limited their
study population to women less than 38 years of age, with
signiﬁcantlyyoungermeanage.Largerstudiesarewarranted,
however, as our numbers of women over the age of 38 are
modest.
More studies, ideally prospective and randomized, are
needed to further investigate the role of eSBT in older
women with blastocysts available for cryopreservation, as
women of advanced maternal age are at particularly high
risk of complications associated with multiple gestations.
Preliminary results suggest that good prognosis patients
undergoing BT, including those of advanced maternal age,
who wish to avoid a multiple gestation should transfer a
single blastocyst, reassured that PRs do not seem to be
signiﬁcantly compromised.
5. Conclusion
Women undergoing eDBT are at uniformly high risk of mul-
tiple gestation regardless of age.eSBT appears to signiﬁcantly
lower the risk of multiple gestation without compromising
PR.
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